Lercanidipine in the Treatment of Hypertension

Beckey, Cherylyn; Lundy, A.; Lutfi, Nahla

doi:10.1345/aph.1h299

Cited by 22 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Switching from a CCB to another because of adverse events is common in daily practice. It is also in accordance with the information derived from other studies, where patients treated with other CCB who experienced typical DHP‐related adverse events were switched from that treatment to lercanidipine with a resulting significant reduction of side effects (Borghi et al 2003; Lund‐Johansen et al 2003; Beckey et al 2007).…”

Section: Discussionsupporting

confidence: 89%

Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study

Barrios

Escobar

Figuera³

et al. 2008

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

The TOLERANCE study was aimed to compare the tolerability of high doses of lercanidipine (20 mg) with that of other frequently used dihydropyridines (amlodipine 10 mg/nifedipine GITS 60 mg) in the treatment of essential hypertension in daily clinical practice. It was an observational, transversal, multicentre study performed in a Primary Care Setting. A total of 650 evaluable patients with essential hypertension and age > or = 18 years were included. They had been treated with high doses of lercanidipine (n= 446) or amlodipine/nifedipine GITS (n= 204) during at least 1 month and previously with low doses (10 mg, 5 mg, and 30 mg, respectively) of the same drugs. The main objective was to compare the rates of vasodilation-related adverse events between both groups. Rates of signs and symptoms related to vasodilation were significantly higher (P < 0.001) in the amlodipine/nifedipine GITS group (76.8%, CI 95%[70.7; 82.9]) than in lercanidipine group (60.8%, [56.1;65.5]). Blood pressure control (< 140/90 mmHg or <130/80 for diabetics) and type of concomitant antihypertensive medications were similar in both groups. Treatment compliance was good (around 93%) and fairly comparable in both groups. Most adverse events with lercanidipine were mild (74.5% vs. 64% in amlodipine/nifedipine GITS group, P= 0.035) whereas severe adverse event rates did not differ significantly between groups (2.8% vs. 3.6%). In conclusion, treatment with lercanidipine at high doses is associated with a lower rate of adverse events related to vasodilation compared to high doses of amlodipine or nifedipine GITS in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 89%

Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study

Barrios

Escobar

Figuera³

et al. 2008

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

show abstract

“…Most data are retrieved from previous excellent reviews. 15,16,33,37,47,48 The main pharmacokinetic characteristics are summarized in Table 1.…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension

Chatzikyrkou

Haller

Menne

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Hypertension is the most important preventable cause of premature death in the developed countries, and the benefi ts of antihypertensive drugs regarding cardiovascular morbidity and mortality are well established. Nevertheless, adequate control is achieved only in the minority of patients. All offi cial guidelines recommend blood pressure targets of 140/90 mmHg in every patient and even lower in high-risk groups, and support the use of two of more drugs as initial therapy in specifi c populations. Multiple drugs acting by different, but complementary, mechanisms of action are increasingly implemented in the treatment of hypertension and fi xed-dose combinations are gaining popularity. Simplifying therapy is particularly important for elderly patients, who are more likely to have co-morbid conditions and to be taking multiple medications. The once-daily administration of a fi xed dose enalapril/lercanidipine effectively reduces blood pressure in patients inadequately controlled by either component, is generally well tolerated and exhibits a favourable metabolic profi le.

show abstract

“…This protracted redistribution helps to avoid reflex tachycardia associated with first-generation dihydropyridines and facilitates a longer duration of action [2]. In addition, LER produces significantly less peripheral edema in patients receiving other dihydropyridines [3] and yields a similar efficacy to that of other antihypertensives [4]. Zanidip 10 and 20 mg film-coated tablets containing LER are approved for the treatment of mild to moderate essential hypertension.…”

Section: Introductionmentioning

confidence: 99%

Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake

Álvarez

Gómez²,

Simón³

et al. 2012

Eur J Clin Pharmacol

View full text Add to dashboard Cite

As intake with a carbohydrate-rich meal is not recommended in the SPC of Zanidip because a twofold difference was considered to be clinically relevant, the intake of lercanidipine only 15 min before food intake does not seem to be consistent with this recommendation. The Marketing Authorisation Holder should clarify the dosing instructions in relation to meals and identify a sufficient time-lapse to ensure an exposure similar to that obtained in phase III clinical efficacy studies.

show abstract

Lercanidipine in the Treatment of Hypertension

Cited by 22 publications

References 34 publications

Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study

Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study

Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension

Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake

Contact Info

Product

Resources

About